Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma With Eosinophilic Phenotype in India.

NCT05384938 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05384938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05384938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma With Eosinophilic Phenotype in India.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
November 19, 2021
Completion date
July 1, 2023
Enrollment
139 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

in adult patients of severe asthma with eosinophilic phenotype in india